Peiling Chen

Peiling Chen

Auto-generated profile, based on publicly available information

Peiling Chen

Department of Thoracic Surgery and Oncology, the First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2024 in Thorax
Verified
Journal Article
Open access
PDF file
WYWenjun Ye
Wenjun Ye
WFWenhai Fu
Wenhai Fu
CLCaichen Li
Caichen Li
JLJianfu Li
Jianfu Li
SXShan Xiong
Shan Xiong
WLWenhua Liang
Wenhua Liang
Background Limited research exists on screening thresholds for low-dose CT in detecting malignant pure ground-glass lung nodules (pGGNs) in the Chinese population. Materials and methods A retrospective analysis of the Guangzhou Lung-Care programme was conducted, retrieving average transverse diameter, location, histopathology, frequency and follow-up intervals. Diagnostic performances for ‘lung cancers’ were evaluated using areas under the curve (AUCs), decision curve analysis (DCA), sensitivities and specificities, with thresholds ranging from 5 mm to 10 mm. We divide malignant pGGNs into three groups: (1) minimally invasive adenocarcinoma (MIA) and invasive adenocarcinoma (IA), (2) atypical adenomatous hyperplasia (AAH) and adenocarcinoma in situ (AIS) and MIA and IA and (3) IA-only. Results In ‘MIA+IA’, increasing the threshold from 5 mm to 8 mm improved specificity (60.97% to 88.85%, p<0.001) and positive predictive values (PPVs; 5.87% to 14.88%, p<0.001), but decreased sensitivity (94.44% to 75.56%, p<0.001). Further raising threshold from 8 mm reduced sensitivity (75.56% to 60.00%, p<0.001), while slightly increasing specificity (88.85% to 93.47%, p<0.001) and PPVs (14.88% to 19.15%, p<0.001). Increasing threshold from 5 mm to 7 mm enhanced the AUC for ‘MIA+IA’ (from 0.711 to 0.829), ‘AAH+AIS+MIA+IA’ (from 0.748 to 0.804) and ‘IA-only’ (from 0.783 to 0.833). At 8 mm, the AUCs for these categories were similar. However, increasing the threshold from 7 mm to 10 mm resulted in reduced AUCs for ‘MIA+IA’ (0.829 to 0.767), ‘AAH+AIS+MIA+IA’ (0.804 to 0.744) and ‘IA-only’ (0.833 to 0.800). DCA reveals that the 8 mm predictive model demonstrates greater clinical utility compared with models with other thresholds. Conclusions Increasing the diameter threshold for positive results for pGGNs, up to 8 mm could enhance diagnostic performance. Trial registration number NCT04938804.

8 December 2023 in Chinese Medical Journal Pulmonary and Critical Care Medicine
Verified
Journal Article
Open access
RZRan Zhong
Ran Zhong
XCXiuyu Cai
Xiuyu Cai
JLJianfu Li
Jianfu Li
PCPeiling Chen
Peiling Chen
RWRunchen Wang
Runchen Wang
JHJianxing He
Jianxing He

1 January 2024 in Therapeutic Advances in Medical Oncology
Verified
Journal Article
Open access
SZShuting Zhan
Shuting Zhan
JLJianfu Li
Jianfu Li
BCBo Cheng
Bo Cheng
CLCaichen Li
Caichen Li
YFYi Feng
Yi Feng
WLWenhua Liang
Wenhua Liang
Background: Real-world data on C-MET protein overexpression in non-small cell lung cancer (NSCLC) patients, particularly among the Asian Chinese population, are limited. Objectives: This study aimed to evaluate the clinicomolecular characteristics and prognosis of C-MET overexpression in Chinese NSCLC patients, focusing on those with positive C-MET overexpression (immunohistochemistry (IHC) 3+). Design: A retrospective and observational study. Methods: Data were collected from NSCLC patients diagnosed at the First Affiliated Hospital of Guangzhou Medical University between November 2006 and April 2021. We identified C-MET overexpression using IHC and C-MET overexpression positivity was defined as IHC 3+ with ⩾50% tumor cells. Additionally, patient genotypes were collected for subgroup analysis. Results: Data from 9785 NSCLC patients were collected. C-MET (−) accounted for 5% (503/9785), C-MET (+) for 27% (2654/9785), C-MET (++) for 36% (3464/9785), and C-MET (+++) for 32% (3164/9785). Genetic testing was available for 4326 patients. Wild-type was observed in 37% (1591 cases), with epidermal growth factor receptor ( EGFR) abnormalities being the most common at 49% (2127 cases). Positive C-MET overexpression correlated significantly with women ( p < 0.001), early-stage ( p = 0.003), adenocarcinoma ( p < 0.001), and driver mutations ( p < 0.001). Patients with anaplastic lymphoma kinase ( ALK) alterations had a higher occurrence of C-MET overexpression positivity (57.1%). Positive C-MET overexpression was significantly associated with EGFR ( p < 0.001), ALK ( p < 0.001), and KRAS alterations ( p = 0.024). Compared to C-MET overexpression (IHC 0), C-MET overexpression (IHC 2+) (hazard ratio (HR) = 0.455, p < 0.001) and C-MET overexpression (IHC 3+) (HR = 0.569, p < 0.001) were correlated with better overall survival in overall NSCLC patients, especially for C-MET overexpression (IHC 2+). Conclusion: Our study elucidates the clinicomolecular characteristics and prognosis of C-MET overexpression in NSCLC patients, particularly those with positive C-MET overexpression (IHC 3+). This provides insight into the prevalence of C-MET overexpression in Chinese NSCLC patients and offers a basis for considering C-MET overexpression as a prognostic and predictive marker in NSCLC.

4 December 2024 in BMJ Open Respiratory Research
Verified
Journal Article
Open access
PDF file
PCPeiling Chen
Peiling Chen
XZXin Zheng
Xin Zheng
CLCaichen Li
Caichen Li
JLJianfu Li
Jianfu Li
CYChen Yang
Chen Yang
WLWenhua Liang
Wenhua Liang
Objectives: This study aims to explore how pre-existing conditions such as blood types, family history of cancer and comorbid diseases correlate with the genetic and programmed death-ligand 1 (PD-L1) expression that contributes to the heterogeneous biological behaviours of non-small cell lung cancer (NSCLC). Materials and methods: A cohort of 5507 NSCLC patients who underwent surgical resection between January 2014 and July 2018 was studied. Targeted next-generation sequencing was used to detect mutations in nine pivotal cancer-related genes, and immunohistochemical staining was applied to assess PD-L1 expression. Logistic regression analysis was employed to identify significant correlations. Results: All patients underwent NGS, with 1839 were also evaluated for PD-L1 expression. Several significant findings were found: ROS1 mutations were closely associated with a family history of lung cancer (OR 7.499, 95% CI 1.094 to 30.940, p=0.013). Epidermal growth factor receptor (EGFR) L858R mutations were common among patients with a family history of non-lung cancers and those with hypertension (OR 2.089, 95% CI 1.029 to 4.135, p=0.037 and OR 1.252, 95% CI 1.001 to 1.562, p=0.048, respectively). Pre-existing conditions such as diabetes and hepatitis B surface antigen positivity (OR 1.468, 95% CI 1.042 to 2.047, p=0.026 and OR 1.373, 95% CI 1.012 to 1.847, p=0.038, respectively) were correlated with EGFR exon 19 deletions. RhD negativity showed potential ties to BRAF mutations (OR 0.010, 95% CI 0.001 to 0.252, p=0.001). A history of tuberculosis linked to increased PD-L1 expression in immune cells (OR 3.597, 95% CI 1.295 to 14.957, p=0.034). Conclusion: This large-scale, cross-sectional study reveals a complex interplay between genetic mutations, immunological features and pre-existing conditions in NSCLC patients, offering insights that could inform personalised treatment strategies.

20 August 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
WYWenjun Ye
Wenjun Ye
BCBo Cheng
Bo Cheng
CLCaichen Li
Caichen Li
XLXiwen Liu
Xiwen Liu
PCPeiling Chen
Peiling Chen
WLWenhua Liang
Wenhua Liang
Background: Chest CT increasingly identifies pulmonary nodules outside organised screening, but national data on prevalence, trends, and management demand in health-examination populations are lacking. Methods: In this retrospective multicentre study, we analysed electronic records from Guangzhou Ping An Healthcare Diagnostic Center’s nationwide health-examination network in China (Jan 1, 2018–Dec 31, 2025) using a validated natural language processing algorithm. We estimated CT use, scan-level nodule frequency, and annual prevalence. Clinically relevant nodules were 5.0–30.0-mm solid or part-solid nodules or 8.0–30.0-mm pure ground-glass nodules. Annual prevalence was age-, sex-, and macroregion-standardised. Findings: During 2018–2025, 1,223,402 participants underwent at least one chest CT. The proportion undergoing CT increased from 8.0% in 2018 to 65.5% in 2025, peaking at 71.1% in 2024. Any pulmonary nodules and clinically relevant nodules were reported on 786,575 (59.2%) and 208,397 (15.7%) examinations and in 714,884 (58.4%) and 190,744 (15.6%) participants, respectively. Annual prevalence per 1000 participants increased from 98.3 (95% CI 52.4–144.2) to 669.2 (610.9–727.5) for any nodule and from 26.2 (14.7–37.7) to 184.4 (165.1–203.7) for clinically relevant nodules. Increases were concentrated in solid and pure ground-glass nodules and those smaller than 10.0 mm. Nodules smaller than 5.0 mm and those measuring 5.0–9.9 mm accounted for 56.0% and 42.6% of the prevalence increase, respectively. Pulmonary tuberculosis and bronchiectasis were associated with higher clinically relevant nodule prevalence. Interpretation: Rising clinically relevant nodule prevalence among health-examination participants, together with expanding CT use, indicates growing potential demand for surveillance and diagnostic assessment.